natgillin/translations-raw huggingface dataset:
150 ml brown glass bottle (type III) with a white child resistant closure (polypropylene) in a cardboard box also containing a 1 ml graduated oral syringe (polypropylene, polyethylene) and an adaptor for the syringe (polyethylene).
Smeđa staklena boca od 150 ml (staklo tip III) s bijelim sigurnosnim zatvaračem za djecu (polipropilen) u kartonskoj kutiji koja također sadrži graduiranu štrcaljku za usta od 1 ml (polipropilen, polietilen) i nastavak za štrcaljku (polietilen).
150 ml brown glass bottle (type III) with a white child resistant closure (polypropylene) in a cardboard box also containing a 3 ml graduated oral syringe (polypropylene, polyethylene) and an adaptor for the syringe (polyethylene).
Smeđa staklena boca od 150 ml (staklo tip III) s bijelim sigurnosnim zatvaračem za djecu (polipropilen) u kartonskoj kutiji koja također sadrži graduiranu štrcaljku za usta od 3 ml (polipropilen, polietilen) i nastavak za štrcaljku (polietilen).
150 ml oral solution
150 ml oralna otopina
150 ml oral solution 150 ml oral solution 300 ml oral solution
150 ml oralne otopine 150 ml oralne otopine 300 ml oralne otopine
150 or 300 mg QD
150 ili 300 mg 1x/dan
150 patients originally randomised to placebo + MTX in Trial 1 received at least one course of RTX + MTX by one year
150 bolesnika prvotno nasumično raspodijeljenih u skupinu koja je primala placebo + metotreksat u Ispitivanju 1 primilo je barem jedan ciklus terapije rituksimab + metotreksat do kraja jedne godine ispitivanja
150 tablets
150 filmom obložene tablete
150 tablets
150 tableta
150 to <300 cells/L
150 do <300 stanica/l
150/100 mg once daily.
150/100 mg jedanput na dan.
150/600/100 mg twice
150/600/100 mg dva
1500 IU octocog alfa
1500 IU oktokoga alfa
1500 mg twice daily
1500 mg dva puta na dan
1512 patients were randomised to and dosed with 125 micrograms Plegridy injected subcutaneously every 2 (n=512) or 4 (n=500) weeks versus placebo (n=500).
1512 bolesnika bilo je randomizirano i primali su dozu od 125 mikrograma Plegridyja injiciranog supkutano svakih 2 (n = 512) ili 4 (n = 500) tjedna u usporedbi s placebom (n = 500).
152 (123,
Svi bolesnici
153 51 Pallini Attiki, Greece
153 51 Pallini Attiki, Grčka
15351 Pallini Attiki Greece
15351 Pallini Attiki Grčka
15351 Pallini Attiki Greece‌‌
15351 Pallini Attiki Grčka
15351 Pallini Attiki, Greece
15351 Pallini Attiki, Grčka
15351 Pallini GREECE
15351 Pallini GRČKA
15351 Pallini, Attiki Greece
15351 Pallini, Attiki Grčka
15Changes in total fasting cholesterol levels from normal at baseline (< 4.39 mmol/l) to high (≥ 5.17 mmol/l) were observed commonly.
15 Često su uočene promjene ukupnog kolesterola natašte od normalnih početnih vrijednosti (< 4,39 mmol/l) do visokih vrijednosti (≥ 5,17 mmol/l).
15e (6.0, 24.5)
15e (6,0, 24,5)
16 (5.0)
Petehije
16 alcohol swabs
16 jastučića natopljenih alkoholom
16 Elevated plasma prolactin levels were reported in 47.4% of adolescent patients.
16 Povišene razine prolaktina u plazmi prijavljene su u 47,4 % adolescentnih bolesnika.
16 Elevated plasma prolactin levels were reported in 47.4% of adolescent patients.
16 Povišene razine prolaktina u plazmi zabilježene su u 47,4 % adolescentnih bolesnika.
16 January 2009
16. siječnja 2009.
16 to 23
16 do 23
16 to 26-year-old women
Žene u dobi od 16 do 26 godina
16 to 26-years of age men
Muškarci u dobi od 16 do 26 godina
16 to 26-years of age women
Žene u dobi od 16 do 26 godina
16 weeks (n = 35)
16 tjedana (n = 35)
16 weeks (n = 63)
16 tjedana (n = 63)
16 weeks (n = 98)a
16 tjedana (n = 98)a
16 weeks after vaccination (Mycoplasma hyopneumoniae)
16 tjedana nakon cijepljenja (Mycoplasma hyopneumoniae)
16 weeks after vaccination (Mycoplasma hyopneumoniae)
16 tjedana nakon cijepljenja (Mycoplasma hyopneumoniae).
16 Weeks N=58
16 tjedana N=58
16 Weeks N=8
16 tjedana N=8
16 weeks of treatment may be associated with a lower chance of response and is associated with a higher risk of relapse than a 24 week treatment duration (see section 5.1).
No 16-tjedno liječenje može biti povezano s manjim izgledima razvijanja odgovora i povezano je s većim rizikom pojave relapsa nego 24-tjedno liječenje (vidjeti dio 5.1).
16% (n = 50)
24% (n = 50)
16% of patients had <6 bone metastases, 44% of patients had between 6 and 20 bone metastases, 40% of patients had more than 20 bone metastases or superscan.
16% bolesnika imalo je <6 koštanih metastaza, 44% bolesnika imalo je između 6 i 20 koštanih metastaza, 40% bolesnika imalo je više od 20 koštanih metastaza ili “superscan”.
16- Through 26-Year-Old Boys and Men
Dječaci i muškarci u dobi od 16 do 26 godina
16- Through 26-Year-Old Girls and Women†
Djevojke i žene u dobi od 16 do 26 godina
16- to 26-Year-Old Men
Muškarci u dobi od 16 do 26 godina
16.1 [15.0, 18.3] (n = 135)
3,7 (3,61; 4,04)
16.1% ; 0.7%
kompleksni parcijalni
16.2% (2.0, 30.5) p=0.0296
16,2% (2,0; 30,5)
16.23. Mean serum HBV DNA by PCR was 7.83 log10 copies/ml and mean serum ALT was 100 U/l; 54% of patients were HBeAg positive, and 35% of patients had LVDr substitutions at baseline.
Srednja vrijednost HBV DNK u serumu mjereno PCR-om bila je 7,83 log10 kopija/ml, srednja vrijednost ALT-a u serumu bila je 100 U/l; 54% bolesnika bilo je HBeAg pozitivno, a 35% bolesnika imalo je LVDr supstitucije na početku ispitivanja.
16.5 mg once daily
16,5 mg jednom dnevno
16.5 mg twice daily
16,5 mg dvaput dnevno
16.7% (Mayo regimen); p <0.0002. The median time to progression was 140 days (capecitabine) vs.
Medijan vremena do progresije bolesti iznosio je 140 dana (kapecitabin) u odnosu na 144 dana (Mayo protokol).
16.8 micrograms
16,8 mikrograma
16.8 mm x 10.3 mm, debossed on one side with “GILEAD” and “4331” and on the other side with “300”.
S utisnutim oznakama „GILEAD” i „4331” na jednoj strani, a na drugoj strani „300”.
16.INFORMATION IN BRAILLE
PODACI NA BRAILLEOVOM PISMU
160 g sachet: do not store above 25 ºC. 400 g sachet: do not store above 25 °C.
Vrećica od 160 g: nemojte čuvati pri temperaturi iznad 25 °C. Vrećica od 400 g: nemojte čuvati pri temperaturi iznad 25 °C.
160 mg single-use vial containing powder for concentrate for infusion solution delivers 8 mL of 20 mg/mL of trastuzumab emtansine after reconstitution
Jedna bočica za jednokratnu uporabu sadrži 160 mg praška za koncentrat za otopinu za infuziju kojim se nakon pripreme dobiva 8 ml trastuzumab emtanzina koncentracije 20 mg/ml.
160 mg single-use vial containing powder for concentrate for infusion solution delivers 8 mL of 20 mg/mL of trastuzumab emtansine after reconstitution (see section 6.6).
Jedna bočica za jednokratnu uporabu sadrži 160 mg praška za koncentrat za otopinu za infuziju kojim se nakon rekonstitucije dobiva 8 ml trastuzumab emtanzina koncentracije 20 mg/ml (vidjeti dio 6.6).
160 mg trastuzumab emtansine vial: Using a sterile syringe, slowly inject 8 mL of sterile water for injection into the vial.
Bočica sa 160 mg trastuzumab emtanzina: Sterilnom štrcaljkom polako ubrizgajte 8 ml sterilne vode za injekcije u bočicu.
160/4.5 µg bd + formoterol 4.5 µg as needed
µg dvaput dnevno + terbutalin 0,4 mg po potrebi
160/4.5 µg bd + terbutaline 0.4 mg as needed
µg dvaput dnevno + terbutalin 0,4 mg po potrebi
1600 (2 x 20 cartridges x 40) tablets (multipack)
1600 (2 x 20 ulošci x 40) tableta (višestruko pakiranje)
160mg/8 ml contains 8 ml of concentrate.
160mg/8 ml sadrži 8 ml koncentrata.
1611 Luxembourg, Luxembourg
1611 Luxembourg, Luksemburg
1611 Luxembourg, Luxembourg.
1611 Luxembourg, Luksemburg
162 avenue Jean Jaurès 69007 Lyon
162 avenue Jean Jaurès F-69007 Lyon
167.8
vrijednosti PVR
168 (2 x 84) tablets
168 (2 x 84) tableta
168 (3 x 56) tablets
168 (3 x 56) tableta
168 (3 x 56) tablets (multipack)
168 (3 x 56) tableta (višestruko pakiranje)
168 (3x56) tablets
168 (3x56) tableta
168 (4 x 42) ampoules (multipack)
168 (4 x 42) ampula (višestruko pakiranje)
168 (4 x 42) ampoules + co- packed with device consumable set (multipack)
168 (4 x 42) ampula pakiranih zajedno sa zamjenskim setom za uređaj (višestruko pakiranje)
168 (4 x 42) AMPOULES WITH 1 ML CO-PACKED WITH BREELIB CONSUMABLES SET
168 (4 x 42) AMPULA S 1 ML PAKIRANIH ZAJEDNO SA ZAMJENSKIM SETOM BREELIB
168 (4 x 42) AMPOULES WITH 1 ML CO-PACKED WITH BREELIB CONSUMABLES SET
168 (4 x 42) AMPULA S 1 ML PAKIRANO ZAJEDNO SA ZAMJENSKIM SETOM BREELIB
168 (4 x 42) tablets
168 (4 x 42) tableta
168 (4x42) ampoules co-packed with Breelib consumables set (containing 1 mouthpiece and 1 medication chamber).
168 (4 x 42) ampula pakiranih zajedno sa zamjenskim setom Breelib (sadrži 1 nastavak za usta i 1 komoru za lijek).
168 capsules
168 kapsula
168 film-coated tablets
56 filmom obloženih tableta 168 filmom obloženih tableta
168 hard capsules
168 tvrdih kapsula
168 mg of maltose per tablet
168 mg na maltozu po tableti
168 tablets
(pojedinačna doza)
168 tablets
168 tableta
168 tablets
EU/1/10/655/005
168 tablets
tableta
168.0 micrograms
168,0 mikrograma
169A,
169 A,
16Elevated plasma prolactin levels were reported in 47.4% of adolescent patients.
16 Povišene razine prolaktina u plazmi zabilježene su u 47,4 % adolescentnih bolesnika.
16mg fluoxetine (as 18.08mg fluoxetine hydrochloride) 32 mg fluoxetine (as 36.16 mg fluoxetine hydrochloride) 64 mg fluoxetine (as 72.34 mg fluoxetine hydrochloride)
16 mg fluoksetina (kao 18,08 mg fluoksetin-hidroklorida) 32 mg fluoksetina (kao 36,16 mg fluoksetin-hidroklorida) 64 mg fluoksetina (kao 72,34 mg fluoksetin-hidroklorida)
17 %
Genotip 2/3
17 days for those treated with pamidronate 90 mg (p-values: 0.001 for 4 mg and 0.007 for 8 mg zoledronic acid).
90 mg (p-vrijednosti: 0,001 za 4 mg i 0,007 za 8 mg zoledronatne kiseline).
17 hours
17 sati
17 ml solution for infusion contains 510 mg of iron as ferumoxytol.
17 ml otopine za infuziju sadrži 510 mg željeza u obliku ferumoksitola.
17 procedures, including 10 dental extractions, were considered minor.
Sedamnaest postupka, uključujući 10 vađenja zuba, smatrali su se manjima.
17 Rue de Pontoise 95520 Osny France
17 Rue de Pontoise 95520 Osny Francuska
17 rue de Pontoise F-95520 Osny
17, Rue de Pontoise F-95520 Osny
17 to < 19
17 do < 19
17.2 mos (13.9, 19.2)
17,2 mjeseci (13,9; 19,2)
17.3 (11.8, NA)
17,3 (11,8; ND)
17.4 mg pyriproxifen, 1,429 mg permethrin
17.4 mg piriproksifena, 1429 mg permetrina
17.5 months; p 0.4146)
(16,2 nasrpam 12,0 mjeseci;
17.5 to 19.3
17,5 do 19,3
17.5 to 5.8 mL/day/kg with an increase in dose from 0.5 to 20 mg/kg, suggesting target-mediated clearance, resulting in greater than proportional increases in Area under the Concentration time curve (AUC).
17,5 na 5,8 ml/dan/kg kada se doza poveća s 0,5 na 20 mg/kg, što ukazuje na klirens posredovan ciljnim mjestom, koji dovodi do više nego proporcionalnih povećanja područja ispod krivulje koncentracija-vrijeme (engl. area under the concentration time curve, AUC).
17.UNIQUE IDENTIFIER – 2D BARCODE
JEDINSTVENI IDENTIFIKATOR – 2D BARKOD
170 00, Praha 7 Czech republic
170 00, Praha 7 Češka Republika
170 00, Praha 7 Czech republic
170 00, Praha 7Češka Republika
170 ml oral solution.
170 ml oralne otopine.
17000 Praha 7 Czech Republic
170 00 Praha 7 Češka
17000 Praha 7 Czech Republic czech.info@valeant.com
170 00 Praha 7 Češka czech.info@valeant.com
171 21 Solna
Uusaru 5
172 rue de Charonne 75011 Paris - France
172 rue de Charonne 75011 Paris - Francuska
17272 (48.9)
OTFC
173 patients completed the study.
173 bolesnika završila su ispitivanje.
174 and 251 head and neck cancer patients who received docetaxel in combination with cisplatin and 5-fluorouracil (clinically important treatment related adverse events are presented).
174 i 251 bolesnika s karcinomom glave i vrata koji su primali docetaksel u kombinaciji s cisplatinom i 5-fluorouracilom (prikazani su klinički značajni štetni događaji povezani s liječenjem).
17493 Greifswald Insel Riems Germany
17493 Greifswald Insel Riems Njemačka
175 film-coated tablets
175 filmom obloženih tableta
175 mg (2.2 ml) twice daily
175 mg (2,2 ml) dva puta na dan
175 mg /
175 tableta
175 mg/43.75 mg/200 mg or 200 mg/50 mg/200 mg) tablets, Corbilta dosing should be carefully titrated for optimal clinical response.
150 mg/37,5 mg/200 mg ili 175 mg/43,75 mg/200 mg ili 200 mg/50 mg/200 mg) tabletama, doziranje Corbilte mora biti pažljivo titrirano radi optimalnog kliničkog odgovora.
175 mg/43.75 mg/200 mg or 200 mg/50 mg/200 mg) tablets, Stalevo dosing should be carefully titrated for optimal clinical response.
125 mg/31,25 mg/200 mg ili 175 mg/43,75 mg/200 mg ili 200 mg/50 mg/200 mg) tabletama, doziranje Staleva mora biti pažljivo titrirano radi optimalnog kliničkog odgovora.
175 mg/43.75 mg/200 mg or 200 mg/50 mg/200 mg) tablets, Stalevo dosing should be carefully titrated for optimal clinical response.
150 mg/37,5 mg/200 mg ili 175 mg/43,75 mg/200 mg ili 200 mg/50 mg/200 mg) tabletama, doziranje Staleva mora biti pažljivo titrirano radi optimalnog kliničkog odgovora.
175 mg/43.75 mg/200 mg) tablets, Levodopa/Carbidopa/Entacapone Orion dosing should be carefully titrated for optimal clinical response.
Levodopa/Carbidopa/Entacapone Oriona mora biti pažljivo titrirano radi optimalnog kliničkog odgovora.
175 tablets
175 tableta
175 tablets
tableta
1750 IU of antithrombin alfa
1750 IU antitrombina alfa
177Lu-Lutetium has a half-life of 6.647 days.
177Lu – lutecij ima vrijeme poluraspada od 6647 dana.
178 of the 580 enrolled patients (30.7%) were defined as having severe disease (CDAI score > 300 and concomitant corticosteroid and/or immunosuppressants) corresponding to the population defined in the indication (see section 4.1).
580 uključenih bolesnika 178 (30,7%) je imalo težak oblik bolesti (CDAI rezultat > 300 uz istodobno uzimanje kortikosteroida i/ili imunosupresiva), što je odgovaralo populaciji definiranoj u indikaciji (vidjeti dio 4.1).
17813 Vall de Bianya Girona
Camprodon, s/n "la Riba" 17813 Vall de Bianya
17813 Vall de Bianya SPAIN
17813 Vall de Bianya ŠPANJOLSKA
17p deletion
delecija 17p
17p or 11q deletion (n=90)
delecija 17p ili 11q (n =90)
17p or 11q deletion (n=90)
delecija 17p ili 11q (n=90)
17β-estradiol is converted reversibly to estrone, and both can be converted to estriol, which is the major urinary metabolite.
17β-estradiol se reverzibilno konvertira u estron, a oba mogu biti konvertirana u estriol, koji je glavni urinarni metabolit.
18 + 14.9
18 postupkom
18 ampoules
18 ampula
18 capsules
18 kapsula
18 G x 2 inch (50 mm) needle.
18 G x 50 mm.
18 March 2015
18. ožujka 2015.
18 mg orally once daily
18 mg peroralno jedanput na dan
18 mg torasemide
18 mg torasemida
18 mg/h) of the above prepared solution over the 3 hour period under adequate medical supervision in an obstetric unit.
18 mg/h) gore navedene pripremljene otopine tijekom 3 sata pod adekvatnim medicinskim nadzorom na odjelu porodništva.
18 million IU
18 milijuna IU
18 million IU solution for injection in multidose pen 1 pen, 12 injection needles and 12 cleansing swabs 2 pens, 24 injection needles and 24 cleansing swabs 8 pens, 96 injection needles and 96 cleansing swabs
18 milijuna IU otopina za injekciju u višedoznoj brizgalici 1 brizgalica, 12 igala za injekciju i 12 tupfera za čišćenje 2 brizgalice, 24 igle za injekciju i 24 tupfera za čišćenje 8 brizgalica, 96 igala za injekciju i 96 tupfera za čišćenje
18 million IU/3mL
10 milijuna IU/ml
18 million IU/3mL
18 milijuna IU/3 ml
18 million IU/3mL
EU/1/99/127/021
18 million IU/pen
18 milijuna IU/brizgalica
18 months
18.
18 months Diluted solution
18 mjeseci Razrijeđena otopina
18 tablets
20 tableta
18 to 59 years N = 99 N = 33
18 do 59 godina N = 99 N = 33
18 – 59 years
18 do 59 godina
18 – 59 years 60 years and above
18 do 59 godina 60 godina i više
18 – 59 years 60 years and above
18 do 59 godina 60 i više godina
18 – 59 years 60 years and above Strain A/Indonesia/05/2005
18 do 59 godina 60 i više godina Soj A/Indonesia/05/2005
18%
F4
18% (17) (p=0.016b)
18% (17) (p=0,016b)
18% (3/17)
(20%, 43%)b
18-23 months after 2 dose
18-23 mjeseca nakon 2. doze
18-23 months after 2nd dose
18-23 mjeseca nakon 2. doze
18-60 years
18-60 godina
18-Month 67%
6 67
18-Month Survival
preživljenje od 18 mjeseci
18-months
18 mjeseci
18.
DRUGO
18.0% p<0.001 (12.0, 23.9)
18,0% p<0,001 (12,0; 23,9)
18.1% vs 0%
18,1% vs 0
18.3 mo (16.6, 21.7)
18,3 mjeseca (16,6; 21,7)
18.4 (17.3, NR)
18,4 (17,3, ND)
18.5% (p<0.0001)
18,5% (p<0,0001)
18.7 (15.6, NE)
18,7 (15,6, NP)
18.7 months median observation time
medijan vremena promatranja: 18,7 mjeseci
18.9 events/1,000 patient-years (p = 0.021) a significant reduction in the absolute risk of myocardial infarction: metformin
18,9 događaja/1000 bolesnik-godini (p=0,021) značajna redukcija apsolutnog rizika za infarkt miokarda: metformin
18.UNIQUE IDENTIFIER - HUMAN READABLE DATA
JEDINSTVENI IDENTIFIKATOR – PODACI ČITLJIVI LJUDSKIM OKOM
180 (3 x 60) capsules
180 (3 x 60) kapsula
180 (3 x 60) film-coated tablets.
180 (3 x 60) filmom obloženih tableta.
180 (3 x 60) tablets
180 (3x60) tableta
180 (3x60) tablets (multipack)
180 (3x60) tableta (višestruko pakiranje)
180 (6 bottles of 30) film-coated tablets
180 (6 bočica s 30) filmom obloženih tableta
180 alcohol swabs
180 vata natopljenih alkoholom
180 capsules
180 kapsula
180 film-coated tablets.
180 filmom obloženih tableta.
180 hard capsules
180 tvrdih kapsula
180 mcg
(N=436)
180 mcg
180 mikrograma
180 mcg
Lamivudin
180 mcg sc qw and a ribavirin dose of 800 mg and were randomised to treatment for either 16 or 24 weeks.
800 mg, a randomizirani su za liječenje ili 16 ili 24 tjedna.
180 mcg x BSA/1.73 m² + Ribavirin 15 mg/kg (N=55)*
180 mikrograma x BSA/1,73 m² + ribavirin 15 mg/kg (N=55)
180 mcg/0.5 ml
180 μg/0,5 ml
180 mcg/1 ml
180 μg/1 ml
180 mg (1.8 ml) twice daily
180 mg (1,8 ml) dva puta na dan
180 mg red, ovaloid tablets with “STARLIX” marked on one side and “180” on the other.
180 mg crvene, ovalne tablete s oznakom „STARLIX“ na jednoj strani te oznakom „180“ na drugoj.
180 mg/ml of tildipirosin
180 mg Tildipirosina
180 mg/ml of tildipirosin
180 mg/ml Tildipirosin
180 mg/ml of tildipirosin
180 mg/ml Tildipirosina
180 micrograms/0.5 ml
180 mikrograma/0,5 ml
180 micrograms/1 ml
180 mikrograma/1 ml
180 ml oral solution
180 ml oralne otopine
180 mL solution in an amber oval 240 mL PET bottle which is delivered with a plastic/foil seal and closed with a child resistant closure composed of HDPE/polypropylene with a pulpboard inner liner.
180 mL otopine u smeđoj ovalnoj PET boci od 240 mL sa plastičnom zaštitnom folijom i sigurnosnim zatvaračem za djecu od HDPE/polipropilena s unutaršnjom oblogom od prešanog kartona.
180 prolonged-release tablets
180 tableta s produljenim oslobađanjem
180 tablets
180 tableta.
180 tablets: EU/1/09/580/019
180 tableta: EU/1/09/580/019
180 tablets: EU/1/09/580/020
180 tableta: EU/1/09/580/020
180 tablets: EU/1/09/580/021
180 tableta: EU/1/09/580/021
180 x 1
180 x 1 kapsula
180 x 1 tablets
180 x 1 tableta
180 g PRE-FILLED PEN
180 µg NAPUNJENA BRIZGALICA
180 g PRE-FILLED SYRINGE
180 µg NAPUNJENA ŠTRCALJKA
180 g VIAL
180 µg BOČICA
180x1 tablets (unit dose)
180x1 tableta (jedinična doza)
182 (n=314)
182 (n= 314)
1831 Diegem Belgium
1831 Diegem Belgija
1831 Diegem Belgium
Belgija
184 micrograms
184 mikrograma
184 micrograms /
184 mikrograma/
185 (98.9%) env genes carried specific substitutions in region of aa 36 - 45 of gp41.
Od toga je 185 (98,9%) gena env nosilo specifične supstitucije u području aminokiselina 36-45 glikoproteina 41.
187 out of 213 patients continued in the safety extension trial.
187 od 213 bolesnika nastavilo je sudjelovanje u produžetku ispitivanja sigurnosti primjene.
188 tablets packaged in a white HDPE bottle with child-resistant polypropylene (PP) closure with aluminium induction seal liner.
188 tableta zapakiranih u bijelu bocu od HDPE-a sa sigurnosnim zatvaračem za djecu od polipropilena (PP) i aluminijskim zaštitnim poklopcem.
189 dogs were treated with Simparica for three months whilst 96 dogs were given another medicine, spinosad.
189 pasa liječeno je VMP-om Simparica tijekom tri mjeseca dok je 96 pasa primilo drugi VMP, spinosad.
19 bleeds were non-joint (soft tissue, muscle, body cavity, intracranial and other) and 7 were joint bleeds of which 1 was a bleed into a target joint.
19 krvarenja nije bilo u zglobovima (meko tkivo, mišić, tjelesna šupljina, intrakranijalno i drugo), a 7 je bilo krvarenje zglobova, od kojih je 1 bilo krvarenje u ciljni zglob.
19 mm x 10.4 mm, debossed on one side with "3641" and plain-faced on the other side of the tablet.
19 mm x 10,4 mm, s utisnutom oznakom "3641" na jednoj strani i bez oznake na drugoj strani tablete.
19 November 2012
19. studeni 2012
19 November 2014
19. studenog 2014.
19 patients were enrolled and 18 patients are on-going in the study.
Uključeno je 19 bolesnika, a 18 bolesnika i sada sudjeluje u ispitivanju.
19 severe)a
19 teško)a
19 to < 22
19 do < 22
19% decrease
19% sniženje
19.1 %
Ninteda
19.17 mg methyl parahydroxybenzoate (E218)
19,17 mg metil-parahidroksibenzoata (E218) 2,13 mg propil-parahidroksibenzoata (E216)
19.2 mo (17.0, 21.0)
19,2 mjeseci (17,0, 21,0)
19.2 mo (17.0, 21.0)
19,2 mjeseci (17,0; 21,0)
19.3% p<0.001 (13.0, 25.6)
19,3% p<0,001 (13,0; 25,6)
19.35 x 9.75 mm.
19,35 mm x 9,75 mm.
19.4 to 21.2
19,4 do 21,2
19.5, 29.6) months
19,5; 29,6) mjeseca
19.6 % (13.8 - 26.6)
Stabilna bolest (%)
19.6 [15.8, NE]
19,6 [15,8; NO]
19.8b
47,8d
19.9% (p<0.0001)
19,9% (p<0,0001)
190 patients entering the study, 57 (30%) had previously been treated with TNF-inhibitor therapy.
Od 190 bolesnika uključenih u ispitivanje, njih 57 (30%) je prethodno bilo na terapiji TNF-inhibitorima.
192]
87b
194 00 Koropi Greece
194 00 Koropi Grčka
195 mg/48.75 mg modified-release hard capsule
Tvrde kapsule s prilagođenim oslobađanjem od 195 mg/48,75 mg
195 mg/48.75 mg modified-release hard capsules
Tvrde kapsule s prilagođenim oslobađanjem od 195 mg/48,75 mg
196 (2 x 98) tablets (multipack)
196 (2 x 98) tableta (višestruko pakiranje)
196 (2x98) tablets
196 (2x98) tableta
196 (7 x 28) tablets
196 (7 x 28) tableta
196 capsules
196 kapsula
196 hard capsules
196 tvrdih kapsula
196 mg dinotefuran,
196 mg dinotefurana,
196 tablets
196 tableta
196 tablets
EU/1/08/455/014
196 tablets
EU/1/08/455/016
196 tablets
EU/1/08/456/014
196 tablets
EU/1/08/457/014
1986 - 2001a
1986. – 2001.a
1986-2001a
1986–2001a
1992 - 2002b
1992. – 2002.b
1992-2002b
1992–2002b
1995 - 2000b
1995. – 2000.b
1995-2000b
1995–2000b
1: adverse reactions noted with increased frequency when bexarotene was administered at a dose
1: nuspojave zabilježene povećanom učestalošću kad se beksaroten primjenjivao u dozi od >300 mg/m2 na dan.
1: Based on post-marketing experience
1 na osnovi iskustva u razdoblju nakon stavljanja lijeka u promet
1: Brache et al, Contraception 2013
1: Brache i sur., Contraception 2013.
1: December
analiza: prosinac
1: Needle cap
1: zatvarač igle
1: Odds ratio: Low Dose/Standard Dose
1: Omjer vjerojatnosti: Niska doza/Standardna doza
1: the event may be a chance finding or related to a mechanism currently not known
1: događaj može biti slučajno otkriće ili povezan s trenutno nepoznatim mehanizmom
1:1 mixture of the equally active regioisomers BPD-MAC and BPD-MAD.
Verteporfin, koji se naziva i monokiselinski derivat benzoporfirina (BPD-MA – benzoporphyrin derivative monoacids), sastoji se od smjese 1:1 jednako djelatnih regioizomera BPD-MAC i BPD- MAD.
1><60><70><70 x 1><98><98 x 1> OLANZAPINE TEVA 10 mg FILM-COATED TABLETS
><98><98 x 1> OLANZAPIN TEVA 10 mg FILMOM OBLOŽENIH TABLETA
1><98><98 x 1> film-coated tablets
><98><98 x 1> filmom obloženih tableta
1a Peel back the seal from the vial adaptor.
1a Odlijepite zaštitni pokrov s nastavka za bočicu.
1A2, 2D6, 2C9, 2C19, 3A4).
Drug Reaction with Eosinophilia and Systemic Symptoms, DRESS)
1adjuvanted by AS04C containing:
1uz dodatak adjuvansa AS04C koji sadrži:
1adsorbed on Al(OH)3 0.5 milligrams Al3+
1adsorbiran na Al (OH)3 0,5 miligrama Al3+
1adsorbed on aluminium hydroxide, hydrated (Al(OH)3) 0.5 milligrams Al3+ 2produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology 3adsorbed on aluminium phosphate (AlPO4) 0.32 milligrams Al3+ 4propagated in VERO cells
1adsorbiran na aluminijev hidroksid, hidratirani (Al(OH)3) 0,5 miligrama Al3+ 2proizveden na stanicama kvasca (Saccharomyces cerevisae) tehnologijom rekombinantne DNA 3adsorbiran na aluminijev fosfat (AlPO4) 0,32 miligrama Al3+ 4 umnožen na VERO stanicama